The content on this site is intended for healthcare professionals only
Cetuximab for NSCLC, from ASCO 2008
Published: 27 Nov 2008
Views: 15854
Professor Nicholas Thatcher
- Categories:
- Lung & pleura
Related Videos
Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year...
Dr Grace Dy - Roswell Park Comprehensive Cancer Center, Buffalo, USA
10 May 2022
Nivolumab plus platinum-doublet chemo vs chemo as neoadjuvant treatment for rese...
Prof Nicolas Girard - Institut Curie, Paris, France
10 May 2022
Recent advances in the treatment of patients with exon 20 insertion-positive NSC...
Dr Alfredo Addeo, Prof Nicolas Girard and Prof Natasha Leighl
21 Apr 2022
Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid ...
Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia
14 Apr 2022
Immune gene signatures for predicting response to neoadjuvant chemoimmunotherapy...
Dr Marta Casarrubios - Hospital Universitario Puerta de Hierro-Majadahonda, Madr...
31 Mar 2022
Real-world increase in biomarker testing in lung cancer
Dr Virginia Calvo de Juan - Hospital Universitario Puerta de Hierro-Majadahonda,...
30 Mar 2022
EGFR testing: Best practice for NSCLC patients with exon 20 insertions
Dr Antonio Passaro, Dr Umberto Malapelle and Dr Joshua Sabari
30 Mar 2022
Lung cancer in India
Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India
3 Feb 2022
Latest in diagnostics in EGFR mutated NSCLC
Dr Neal Lindeman - Brigham and Women's Hospital, Boston, USA
3 Dec 2021